Previous research demonstrated that the formation of PTEN-null tumors usually depends on the p100β catalytic isoform of PI3K (PI3Kβ); however, the mechanisms behind this dependency are unknown. In a recently published study, researchers from Dana-Farber Cancer Institute aimed to assess the role of PI3Kβ in immune evasion in PTEN-null breast cancer.